[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100577171":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":12,"locations":18,"responsibleParty":33,"collaborators":36,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":48,"sex":54,"minAge":55,"maxAge":7,"enrollmentInfo":56,"targetDuration":7,"studyType":59,"phases":7,"briefSummary":60,"conditions":61,"keywords":7,"overallStatus":20,"whyStopped":7,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},{"fullName":5,"class":6},"Leiden University Medical Center","OTHER",null,[9],{"name":10,"affiliation":5,"role":11},"Y.K. Onno Teng","PRINCIPAL_INVESTIGATOR",[13],{"name":14,"role":15,"phone":16,"phoneExt":7,"email":17},"Y.K.O. Teng, MD, PhD","CONTACT","+31715262148","y.k.o.teng@Lumc.nl",[19],{"facility":5,"status":20,"city":21,"state":7,"zip":7,"country":22,"countryCode":23,"cosmosGeoPoint":24,"geoPoint":29,"contacts":30},"RECRUITING","Leiden","Netherlands","NL",{"type":25,"coordinates":26},"Point",[27,28],4.49306,52.15833,{"lat":28,"lon":27},[31],{"name":32,"role":15,"phone":7,"phoneExt":7,"email":17},"YKO Teng, MD, PhD",{"type":11,"investigatorFullName":34,"investigatorTitle":35,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"Y.K.Onno Teng","Clinical Professor",[37,39,41,43],{"name":38,"class":6},"University of Udine",{"name":40,"class":6},"University of Modena and Reggio Emilia",{"name":42,"class":6},"Hospital Universitari de Bellvitge",{"name":44,"class":45},"ZOL Hospital Genk Belgium","UNKNOWN","100577171","early-access-avacopan-in-real-world-anca-associated-vasculitis-100577171",false,"NCT06794827","Early-access Avacopan in Real-world ANCA-associated Vasculitis","Evaluating Clinical Practice of Early Access Avacopan Treatment for ANCA-associated Vasculitis in European Countries","AVAC-EUR","Inclusion Criteria:\n\n* Established diagnosis of GPA or MPA\n* Treatment (initiation) with avacopan\n* Informed consent for use of medical data\n\nExclusion Criteria:\n\n* If there is no AAV disease activity present that can be supported by an objectifiable clinical measure or assessment\n* If a subject is below 16 years old","ALL","16 Years",{"count":57,"type":58},100,"ESTIMATED","OBSERVATIONAL","The current study proposal aims to investigate the clinical practice variation of the initial use of avacopan for AAV patients in Europe. The study will describe patient characteristics and organ-specific clinical benefit of avacopan treatment in a unique, first-experience cohort of AAV patients. By studying the clinical practice variation of first-experience avacopan treatment, this study will be uniquely positioned to identify pivotal issues on the real-life implementation of avacopan treatment. These observational data can ultimately serve to address current knowledge gaps on avacopan treatment in AAV patients, improve the care and drug-access for AAV patients with avacopan treatment and generate new areas of research.",[62],"ANCA Associated Vasculitis","2025-01-22",{"date":65,"type":66},"2025-01-27","ACTUAL",{"date":68,"type":66},"2023-11-01",{"date":70,"type":58},"2026-12-31",{"name":5,"class":6},1]